Omalizumab biosimilar is under clinical development by Kashiv BioSciences and currently in Phase I for Asthma. According to GlobalData, Phase I drugs for Asthma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Omalizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Omalizumab biosimilar overview
Omalizumab biosimilar is under development for the treatment of Asthma, chronic idiopathic urticaria. It is developed based on MayaBio reactor technology. The drug candidate is administered through subcutaneous route. It acts by targeting immunoglobulin E.
Kashiv BioSciences overview
Kashiv BioSciences (Kashiv) formerly known as Kashiv Pharma, is a pharmaceutical research company. It develops drug delivery platforms to create improved versions of medicines for patients and physicians. The company also develops innovative technologies, medicines, and life cycle management products. Kashiv provides services such as formulation development, analytical development and clinical supply manufacturing. It also offers contract research and development services to the pharmaceutical sector. Kashiv provides advanced deterrent technologies, formulation and controlled release technologies. The company works in partnership with pharmaceutical companies to commercialize its products. It operates a research and development facility in the US. Kashiv is headquartered in Bridgewater, New Jersey, the US.
For a complete picture of Omalizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.